INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) is the most common malignancy of the kidney with near 338.000 new diagnoses per year worldwide \[[@R1]\]. It is more frequent in men and 75% of the patients are diagnosed over 60 years of age. Incidence of RCC has increased steadily at 2% per year contributing to about 144.000 deaths in 2012 \[[@R2], [@R3]\]. Diverse histological variants have been described including clear cell (75%), papillary (10%), chromophobe (5%) and others \[[@R4]\]. Approximately 25% of the patients present with advanced disease at diagnosis, and up to one third of those with localized disease that undergo surgery with a curative intention will recur requiring systemic treatment \[[@R5]\].

A better understanding of the molecular biology of RCC has allowed remarkable progress in therapeutics in the last decade. This advance comes primarily from the description of the Von Hippel -Lindau (VHL) syndrome; a hereditary condition associated with a mutation in the homonymous tumor suppressor gene, in which around 60% of the patients develop clear cell RCC (ccRCC). In normal conditions the VHL product (VHLp) creates a complex that targets hypoxia inducible factors 1 and 2 (HIF 1-2) for ubiquitin-mediated degradation. In the absence of VHLp by either mutation or methylation of VHL gene, HIF accumulates leading to exaggerated transcription of multiple genes involved in cell proliferation and angiogenesis such as the platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and transforming growth factor \[[@R6]--[@R9]\]. The VEGF binds its receptor (VEGFR) and promotes proliferation and migration of endothelial cells, increased vascular permeability and revascularization during tumor development \[[@R10]--[@R12]\]. Similarly, PDGF and its receptors (PDGFRA, PDGFRB) play a critical role in regulating angiogenesis through controlling functions during the mesenchymal cell development. Signalling through PDGF also promotes cell migration, survival and proliferation and indirectly regulates angiogenesis by inducing transcription and secretion of VEGF \[[@R13]\]. These knowledge and the observation that around 90% of sporadic ccRCC have abnormal function of VHL has led to an intense drug development in RCC targeting VEGF, PDGF or their cognate receptors. Bevacizumab, a humanized monoclonal antibody against VEGF, was the first agent in this class to demonstrate activity in advanced RCC \[[@R14]\]. Thereafter multiple antiangiogenics such as the tyrosine kinase inhibitors sunitinib, sorafenib, pazopanib or axitinib and mTOR inhibitors such as temsirolimus or everolimus, have shown remarkable activity in advanced RCC becoming standard of treatment in different settings \[[@R15]\]. More recently other therapeutic strategies such as targeting the program-death 1 (PD-1) receptor or the hepatocyte growth factor receptor (MET) have also succeeded \[[@R16], [@R17]\].

Although the availability of all these drugs has improved substantially the therapeutic results in RCC, approximately 40% of patients treated in first-line will not achieve an objective response and about 20--25% will present an early progression. Currently available prognostic systems fail to identify these patients and no adequate predictive factors of response have been validated in advanced RCC yet.

The variability in the genetic constitution of the individual in critical genes related to disease mechanisms or anti-cancer drug metabolism could explain this variable clinical course. Single nucleotides polymorphisms (SNPs) are the most common genetic variations in the DNA sequence, involve a single base and have a frequency of greater than 1% in at least one minor allele population \[[@R18]\]. Certain SNPs have already been identified as potential predictors of efficacy and/or toxicity in advanced RCC patients treated with tyrosine kinase inhibitors \[[@R19]--[@R26]\].

The present study aims to analyse the incidence of SNPs in genes related with angiogenesis or metabolism of antiangiogenics in patients with localized and advanced RCC and to test their potential as prognostic and/or predictive factors.

RESULTS {#s2}
=======

One hundred and two patients were initially included in the study, 65% were male and the median age was 62 years (range 29--83 years). Three patients were excluded from the final analysis due to incomplete clinical information available. The median of follow-up was 62 months. Table [1A](#T1A){ref-type="table"} shows clinical characteristics for localized (a) and metastatic (b) patients and the association of these characteristics with disease/progression free survival (DFS and PFS) and overall survival (OS) ([c](#T1C){ref-type="table"}).

###### Clinical features of patients with localized disease. *N* = number of patients, % = percentage of patients, Total = total of patients

  Clinical feature           *N*      \%       Total
  -------------------------- -------- -------- --------
  **Gender**                                   
   Male                      45       62%      73
   Female                    28       38%      
  **Age**                                      
   ≥60                       45       62%      73
   \<60                      28       38%      
  **Diagnosis**                                
   Incidental                36       49%      73
   Back Pain                 1        1%       
   Hematuria                 8        11%      
   Constitutional symptoms   4        6%       
   Others                    24       33%      
  **Nephrectomy**                              
   Yes                       73       100%     73
   No                        **--**   **--**   
   Partial                   3        4%       73
   Complete                  70       96%      
   Open surgery              64       88%      73
   Laparoscopy               9        12%      
  **Histology**                                
   Clear cell                54       74%      73
   Papillary                 16       22%      
   Other                     3        4%       
  **Furhman Grade**                            
   1                         24       36%      66^\*^
   2                         21       32%      
   3                         18       27%      
   4                         3        5%       
  **Furhman Grade Groups**                     
   1--2                      46       70%      66^\*^
   3--4                      20       30%      
  **Diagnosis TNM**                            
   T1--T2                    54       74%      73
   T3--T4                    19       26%      
  **ECOG**                                     
   0                         20       83%      24^\*^
   \>0                       4        17%      

^\*^*Only available data is presented.*

###### Clinical features of patients with metastatic disease. *N* = number of patients, % = percentage of patients, Total = total of patients

  Clinical feature                                           *N*   \%    Total
  ---------------------------------------------------------- ----- ----- --------
  **Gender**                                                             
   Male                                                      35    70%   50
   Female                                                    15    30%   
  **Age**                                                                
   ≥60                                                       22    44%   50
   \<60                                                      28    66%   
  **Diagnosis**                                                          
   Incidental                                                15    30%   50
   Back Pain                                                 2     4%    
   Hematuria                                                 8     16%   
   Constitutional symptoms                                   6     12%   
   Others                                                    19    38%   
  **Nephrectomy**                                                        
   Yes                                                       43    86%   50
   No                                                        7     14%   
   Partial                                                   1     2%    43
   Complete                                                  42    98%   
   Open surgery                                              39    91%   43
   Laparoscopy                                               4     9%    
  **Histology**                                                          
   Clear cell                                                41    82%   50
   Papillary                                                 5     10%   
   Other                                                     4     8%    
  **Furhman Grade**                                                      
   1                                                         7     18%   38^\*^
   2                                                         12    32%   
   3                                                         13    34%   
   4                                                         6     16%   
  **Furhman Grade Groups**                                               
   1--2                                                      19    50%   38^\*^
   3--4                                                      19    50%   
  **Diagnosis TNM**                                                      
   T1--T2                                                    15    30%   50
   T3--T4                                                    35    70%   
  **ECOG**                                                               
   0                                                         33    66%   50
   \>0                                                       17    34%   
  **Metastasis**                                                         
   Lung                                                      34    68%   50
   Liver                                                     7     14%   
   Nodes                                                     16    32%   
   Bones                                                     6     12%   
   Brain                                                     1     2%    
  **MSKCC prognosis (Karnofsky Hemoglobin, LDH, calcium)**               
  **Karnofsky**                                                          
   ≥80%                                                      45    90%   50
   \<80%                                                     5     10%   
  **Hemoglobin**                                                         
   \<LLN                                                     22    44%   50
   Normal                                                    28    56%   
  **LDH**                                                                
   ≥1.5 ULN                                                  2     4%    50
   \<1.5 ULN                                                 48    96%   
  **Corrected calcium**                                                  
   ≥10 mg/dl                                                 1     2%    50
   \<10 mg/dl                                                49    98%   
  **Time nephrectomy-systemic treatment**                                
   ≥1 year                                                   21    42%   50
   \<1 year                                                  29    58%   
  **Prognosis Group**                                                    
   Favorable                                                 12    24%   50
   Intermediate                                              30    60%   
   Poor                                                      8     16%   
  **Systemic treatment**                                                 
   TKI                                                       43    86%   50
    Sunitinib                                                33          
    Pazopanib                                                10          
   mTOR                                                      7     14%   
    Temsirolimus                                             5           
    Everolimus                                               2           

^\*^*Only available data is presented.*

###### Clinical features of patients associated with Disease Free Survival (DFS) or Progression Free Survival (PFS) and Overall Survival (OS) ( *p* values \> 0.999 not shown)

  Patients                                               Localized disease ( *p*)   Metastatic disease ( *p*)           
  ------------------------------------------------------ -------------------------- --------------------------- ------- -------
  Gender                                                 0.345                      0.767                       0.493   0.470
  Age (≥60 vs \<60)                                      0.440                      0.570                       0.108   0.773
  Diagnosis (incidental vs others)                       0.499                      0.832                       --      --
  Nephrectomy (yes/no)                                   NA                         0.660                       0.080   
    Partial/Complete                                     0.230                      --                          --      0.395
    Open surgery/ Laparoscopy                            0.900                      0.426                       0.563   0.140
  Histology (clear cell vs papillary vs others)          0.997                      0.491                       0.381   0.168
  Furhman Grade (1--2 vs 3--4)                           0.185                      0.328                       0.027   --
  TNM (T1--T2 vs T3--T4)                                 0.001                      0.055                       0.170   0.474
  ECOG (0 vs \>0)                                        --                         0.064                       0.173   0.017
  Metastasis                                                                                                            
   Lung                                                                                                         0.179   0.118
   Liver                                                                                                        --      0.210
   Nodes                                                                                                        0.731   0.357
   Bones                                                                                                        --      0.083
   Brain                                                                                                        --      --
  Karnofsky (≥80% vs \<80%)                              NA                         0.309                       0.152   
  Hemoglobin (\<LLN vs normal)                                                                                  0.339   0.036
  LDH (≥1.5 ULN vs \<1.5 ULN)                                                                                   --      0.542
  Corrected calcium (≥10 vs \<10 mg/dl)                                                                         --      --
  Time nephrectomy-systemic treatment (≥1 vs \<1 year)                                                          0.027   0.020
  Prognosis Group (Favorable vs Intermediate/Poor)                                                              0.01    0.001
  Systemic treatment (TKI vs mTor)                                                                              --      0.235

NA: Not apply for patients with localized disease.

One triallelic SNP (rs2032582) was excluded from the analysis due to inconsistent results with the array utilized. The minor allele frequencies (MAF) of the others 62 polymorphisms genotyped (Table [2](#T2){ref-type="table"}) were consistent with the data described elsewhere for European and Iberian population (1000 genomes, dbSNP database) and all SNPs were in Hardy-Weinberg equilibrium ( *p \>* 0.05). Table [2](#T2){ref-type="table"} shows the characteristics for the 62 polymorphisms genotyped and frequency in our tumor samples in localized and metastatic patients.

###### Characteristics for the 62 polymorphisms genotyped and frequency in our tumor samples in localized and metastatic patients

  ------------------------------------------------------------------------------------------------------------------------------------------------
       dbSNP        Gene      Chrom.    HGVS name           Location      Type of SNP\                 Minor allele   *N* Localized   *N*\
                                                                          variant                                                     Metastatic
  ---- ------------ --------- --------- ------------------- ------------- ---------------------------- -------------- --------------- ------------
  1    rs699947     VEGFA     6p21.1    6:g.43736389A\>C    6:43736389    Upstream gene                A (46.7)       43 (58.9)       16 (61.5)

  2    rs833061     VEGFA     6p21.1    6:g.43737486C\>T    6:43737486    Upstream gene                C (47.2)       41 (56.2)       16 (61.5)

  3    rs3025010    VEGFA     6p21.1    6:g.43747577T\>C    6:43747577    Non coding transcript exon   C (36)         36 (49.3)       17 (65.4)

  4    rs3025033    VEGFA     6p21.1    6:g.43751075A\>G    6:43751075    Non coding transcript exon   G (15)         22 (30.1)       8 (30.8)

  5    rs2010963    VEGFA     6p21.1    6:g.43738350C\>G    6:43738350    5 prime UTR                  C (33.6)       37 (50.7)       11 (42.3)

  6    rs1570360    VEGFA     6p21.1    6:g.43737830A\>G    6:43737830    Upstream gene                A (30)         15 (20.5)       1 (3.8)

  7    rs3025039    VEGFA     6p21.1    6:g.43752536C\>T    6:43752536    3 prime UTR                  T (13)         15 (20.5)       6 (23.1)

  8    rs4930152    VEGFB     11q13.1   11:g.64005412G\>A   11:64005412   Intron variant               A (31)         37 (50.7)       69.2 (18)

  9    rs594942     VEGFB     11q13.1   11:g.64006292T\>C   11:64006292   Upstream gene                T (30)         45 (61.6)       14 (53.8)

  10   rs2016110    VEGFC     4q34.3    4:g.177604081A\>G   4:177604081   Intron                       A (13)         25 (34.2)       8 (30.8)

  11   rs1485766    VEGFC     4q34.3    4:g.177610884T\>G   4:177610884   Intron                       G (49)         42 (57.5)       12 (46.2)

  12   rs11947611   VEGFC     4q34.3    4:g.177611397G\>A   4:177611397   Intron                       A (46)         32 (43.8)       10 (38.5)

  13   rs2877967    VEGFC     4q34.3    4:g.177707602C\>T   4:177707602   Intron                       C (14)         17 (23.3)       4 (15.4)

  14   rs4604006    VEGFC     4q34.3    4:g.177608775T\>C   4:177608775   Intron                       T (27)         24 (32.9)       12 (46.2)

  15   rs2305948    VEGFR2    4q12      4:g.55979558C\>T    4:55979558    Missense                     T (14)         21 (28.8)       4 (15.4)

  16   rs1870377    VEGFR2    4q12      4:g.55972974T\>A    4:55972974    Missense                     A (25)         21 (28.8)       6 (23.1)

  17   rs12505758   VEGFR2    4q12      4:g.55966898T\>C    4:55966898    Intron                       C (12)         26 (19)         19.2 (5)

  18   rs10013228   VEGFR2    4q12      4:g.55997340A\>G    4:55997340    Intergenic                   G (30)         32 (43.8)       11 (42.3)

  19   rs11941492   VEGFR2    4q12      4:g.55978210C\>T    4:55978210    Intron                       T (22)         25 (34.2)       7 (26.9)

  20   rs2071559    VEGFR2    4q12      4:g.55992366A\>G    4:55992366    Upstream gene                A (47)         50 (68.5)       16 (61.5)

  21   rs1531290    VEGFR2    4q12      4:g.55986562G\>A    4:55986562    Intron                       A (47)         41 (56.2)       15 (57.7)

  22   rs6828477    VEGFR2    4q12      4:g.55966801C\>T    4:55966801    Intron                       C (43)         18 (24.7)       10 (38.5)

  23   rs307826     VEGFR3    5q35.3    5:g.180051003T\>C   5:180051003   Missense                     C (12)         9 (12.3)        5 (19.2)

  24   rs307821     VEGFR3    5q35.3    5:g.180030313C\>A   5:180030313   Missense                     A (11)         8 (11)          1 (3.8)

  25   rs6877011    VEGFR3    5q35.3    5:g.180029471C\>G   5:180029471   3 prime UTR                  G (6)          6 (8.2)         5 (19.2)

  26   rs779805     VHL       3p25.3    3:g.10183337G\>A    3:10183337    5 prime UTR                  G (28)         25 (34.2)       9 (34.6)

  27   rs1642742    VHL       3p25.3    3:g.10191943G\>A    3:10191943    3 prime UTR                  G (29)         28 (38.4)       15 (57.7)

  28   rs2227543    IL8       4q13.3    4:g.74607910C\>T    4:74607910    3 prime UTR                  T (42)         37 (50.7)       14 (53.8)

  29   rs4073       IL8       4q13.3    4:g.74606024A\>T    4:74606024    Upstream gene                A (47)         30 (41.1)       11 (42.3)

  30   rs1800795    IL6       7p15.3    7:g.22766645C\>G    7:22766645    Intron                       C (35)         36 (49.3)       17 (65.4)

  31   rs1045642    ABCB1     7q21.12   7:g.87138645A\>T    7:87138645    Synonymous                   A (46)         46 (63)         20 (76.9)

  32   rs1128503    ABCB1     7q21.12   7:g.87179601A\>G    7:87179601    Synonymous                   A (38)         51 (69.9)       18 (69.2)

  33   rs2231142    ABCG2     4q22.1    4:g.89052323G\>T    4:89052323    Missense                     T (7)          5 (6.8)         3 (11.5)

  34   rs3814055    NR1I2     3q13.33   3:g.119500035C\>T   3:119500035   5 prime UTR                  T (40)         47 (64.4)       15 (57.7)

  35   rs2276707    NR1I2     3q13.33   3:g.119534153C\>T   3:119534153   Intron                       T (18)         21 (28.8)       13 (50)

  36   rs2307424    NR1I3     1q23.3    1:g.161202605G\>A   1:161202605   Synonymous                   A (35)         32 (43.8)       16 (61.5)

  37   rs4073054    NR1I3     1q23.3    1:g.161200487C\>A   1:161200487   3 prime UTR                  C (34)         34 (46.6)       11 (42.3)

  38   rs2740574    CYP3A4    7q22.1    7:g.99382096C\>T    7:99382096    Upstream gene                C (3)          3 (4.1)         1 (3.8)

  39   rs776746     CYP3A5    7q22.1    7:g.99270539C\>T    7:99270539    Splice acceptor              T (7)          9 (12.3)        4 (15.4)

  40   rs9800958    PRKAR1B   7p22.3    7:g.668723A\>G      7:668723      Intron                       A (27)         59 (80.8)       20 (76.9)

  41   rs9768991    PRKAR1B   7p22.3    7:g.671687T\>C      7:671687      Intron                       T (27)         25 (34.2)       9 (34.6)

  42   rs9611117    PDGFB     22q13.1   22:g.39624105T\>G   22:39624105   Intron                       G (45)         51 (69.9)       14 (53.8)

  43   rs879180     PDGFB     22q13.1   22:g.39631547T\>C   22:39631547   Intron                       T (26)         26 (35.6)       11 (42.3)

  44   rs35597368   PDGFRA    4q12      4:g.55139771T\>C    4:55139771    Missense                     C (8)          8 (11)          7 (26.9)

  45   rs2114039    PDGFRA    4q12      4:g.55092626T\>C    4:55092626    Intron                       C (30)         28 (38.4)       9 (34.6)

  46   rs6554162    PDGFRA    4q12      4:g.55093955G\>A    4:55093955    Intron                       A (30)         31 (42.5)       11 (42.3)

  47   rs1800812    PDGFRA    4q12      4:g.55094629G\>T    4:55094629    Intron                       T (20)         20 (27.4)       7 (26.9)

  48   rs4358459    PDGFRA    4q12      4:g.55133726T\>G    4:55133726    Synonymous                   G (10)         9 (12.3)        6 (23.1)

  49   rs2228230    PDGFRA    4q12      4:g.55152040C\>T    4:55152040    Synonymous                   T (13)         12 (16.4)       4 (15.4)

  50   rs17739921   PDGFRA    4q12      4:g.55164866A\>C    4:55164866    Downstream gene              C (47)         51 (69.9)       15 (57.7)

  51   rs246395     PDGFRB    5q32      5:g.149499672T\>C   5:149499672   Synonymous                   C (27)         44 (60.3)       22 (84.6)

  52   rs246394     PDGFRB    5q32      5:g.149498151G\>A   5:149498151   Intron                       A (25)         35 (47.9)       10 (38.5)

  53   rs3816018    PDGFRB    5q32      5:g.149508475C\>T   5:149508475   Intron                       C (44)         39 (53.4)       15 (57.7)

  54   rs17708574   PDGFRB    5q32      5:g.149521238G\>A   5:149521238   Intron                       A (16)         13 (17.8)       9 (34.6)

  55   rs2302273    PDGFRB    5q32      5:g.149535255G\>A   5:149535255   5 prime UTR                  A (24)         33 (45.2)       6 (23.1)

  56   rs3828610    PDGFRB    5q32      5:g.149535625A\>C   5:149535625   Upstream gene                C (41)         39 (53.4)       10 (38.5)

  57   rs2304060    PDGFRB    5q32      5:g.149501751A\>C   5:149501751   Non coding transcript exon   C (43)         47 (64.4)       17 (65.4)

  58   rs17656204   PDGFRB    5q32      5:g.149501803C\>T   5:149501803   Intron                       T (26)         38 (52.1)       13 (50)

  59   rs11748255   PDGFRB    5q32      5:g.149512042G\>A   5:149512042   Intron                       A (48)         43 (58.9)       18 (69.2)

  60   rs11740355   PDGFRB    5q32      5:g.149513626T\>G   5:149513626   Non coding transcript exon   G (8)          6 (8.2)         2 (7.7)

  61   rs3776081    PDGFRB    5q32      5:g.149532107T\>C   5:149532107   Intron                       C (37)         40 (54.8)       14 (53.8)

  62   rs4324662    PDGFRB    5q32      5:g.149531111C\>T   5:149531111   Intron                       T (24)         31 (42.5)       8 (30.8)
  ------------------------------------------------------------------------------------------------------------------------------------------------

Chrom: Chromosome, Minor allele frequency for European or Iberian population (%). *N*: number of patients with the minor allele frequency (%).

Upstream gene: the sequence variant is located in the 5′ position of the gene.

Downstream gene: the sequence variant is located in the 3′ position of the gene.

Patients were classified in two cohorts for analysis purposes: localized and metastatic. A number of SNPs showed either a protective or adverse effect (Table [3A](#T3A){ref-type="table"}). Thus, in patients with localized tumors, one polymorphism, rs2071559 in VEGFR2 gene was associated with a protective effect: the mean of patients with this SNP presented a DFS of 49 month vs. 19 months when the SNP was absent. Another two, rs2228230 and rs10013228 in two genes (PDGFRA and VEGFR2) were significantly associated with worse DFS in the multivariate analysis. Accordingly, the absence of rs2228230 associated with an increased DFS (43 months) compared with 25 months in those patients harbouring the SNP. For rs10013228 the deleterious effect in DFS was even of a larger magnitude (62 months vs. 31 months). Additionally, rs10013228 was also significantly associated with a shorter OS (136 vs. 120 months). Other two SNPs (rs307826 and rs6877011) in VEGFR3 were also confirmed as predictors of shorter OS (127 vs. 96 months and 139 vs. 30 months, respectively).

###### Most representative SNPs in patients with localized disease

  dbSNP        Gene     DFS \[Months (m)\]                          
  ------------ -------- -------------------- ----------- ---------- -----
  rs2071559    VEGFR2   49 vs 19 m           **0.003**   **0.01**   0.2
  rs10013228   VEGFR2   31 vs 62 m           0.07        **0.03**   4.6
  rs1870377    VEGFR2   23 vs 51 m           **0.03**    0.08       3.5
  rs2228230    PDGFRA   25 vs 43 m           0.21        **0.01**   21

  dbSNP        Gene     OS \[Months (m)\]                           
  ------------ -------- ------------------- ----------- ----------- -----
  rs10013228   VEGFR2   120 vs 136 m        **0.04**    **0.01**    5.5
  rs2305948    VEGFR2   103 vs 138 m        **0.04**    0.06        2.9
  rs307826     VEGFR3   96 vs 127 m         0.10        **0.03**    3.6
  rs6877011    VEGFR3   30 vs 139 m         **0.001**   **0.003**   5.5

DFS: disease free survival, OS: overall survival, UV: univariant analysis, MV: multivariant analysis, HR: hazard ratio.

In metastatic patients, two SNPs: rs9800958 (PRKAR1B) ( *p =* 0.05) and rs2302273 (PDGFRB) ( *p =* 0.05), showed a tendency towards a better OS in the multivariant analysis (Table [3B](#T3B){ref-type="table"}). In terms of activity, two SNPs correlated with better response rate (RR): rs2016110 (VEGFC) ( *p =* 0.07) and rs594942 (VEGFB) ( *p =* 0.03) and another two: rs699947and rs3025010 (VEGFA) ( *p \<* 0.005) associated with a worse RR (Table [3C](#T3C){ref-type="table"}). DFS and OS curves for statistically significant SNPs are illustrated in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. When analyzing the predictive role of clinical variables, in the localized disease cohort, TNM stage T1 or T2 associated with a better DFS ( *p =* 0.001) and OS ( *p =* 0.055). In metastatic patients, Fuhrman grade (1--2) ( *p =* 0.027) correlated with better progression free survival (PFS) and normal hemoglobin ( *p =* 0.036) and ECOG 0 were significant for a better OS. Intermediate or poor prognosis ( *p* ≤ 0.01) and time between nephrectomy and systemic treatment (˃1 year) ( *p =* 0.020) were associated with both, shorter PFS and OS.

###### Most representative SNPs in patients with metastatic disease

  dbSNP       Gene      OS \[Months (m)\]                      
  ----------- --------- ------------------- ----------- ------ -----
  rs9800958   PRKAR1B   32 vs 14 m          **0.03**    0.05   0.3
  rs2302273   PDGFRB    42 vs 19 m          **0.014**   0.05   0.1

OS: overall survival, UV: univariant analysis, MV: multivariant analysis, HR: hazard ratio.

###### Most representative SNPs in patients with metastatic disease

  ---------------------------------------------------------------------------------------
  dbSNP       Gene    Result SNP present   RR   Total\   ( *p*)               
                                                (*n*)                         
  ----------- ------- -------------------- ---- -------- -------- ----------- -----------
  rs2016110   VEGFC   Better prognosis     19   4        23       **0.009**   0.07

  rs594942    VEGFB   Better prognosis     16   4        20       **0.025**   **0.03**

  rs699947    VEGFA   Worse prognosis      8    23       31       **0.01**    **0.004**

  rs3025010   VEGFA   Worse prognosis      7    23       30       **0.009**   **0.002**
  ---------------------------------------------------------------------------------------

RR: response rate, UV: univariant analysis, MV: multivariant analysis. (n): number of patients.
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DISCUSSION {#s3}
==========

Despite major advances in the knowledge of the molecular basis and therapeutics of RCC, prognostic and predictive estimation remains largely based on clinical and blood test parameters. This is an exploratory pharmacogenetic study designed to identify SNPs that could contribute to select patients with better prognosis and /or higher chances of benefiting from systemic treatment. We studied 62 polymorphisms from 18 genes in 99 patients on the basis of allele frequency and functionality evidence. Our study showed that the presence of certain SPNs was statistically associated with the progression of the disease, the response to treatment and the overall survival in this RCC patient population.

In patients with localized disease, the SNPs that had clinical significance were those positioned in receptors of VEGF and PDGF such as VEGFR2, VEGFR3 or PDGFR. SNPs located in these genes could potentially influence the activation of their cognate signaling pathways, which is a well-established mechanism of RCC tumorigenesis. We found that patients wild type for rs10013228 have a better DFS and OS. No studies in European populations or in RCC patients have been found in this regard. To our knowledge, the only reference in the literature of this SNP comes from a Chinese cohort of localized colorectal cancer patients where it had shown a protective effect \[[@R27]\]. Rs2071559 is a promoter SNP associated with VEGFR2 transcription activity \[[@R28]\]. In our study the AA genotype was associated with a protective effect increasing the DFS. These results are in concordance with data from other reported studies. In a recent metastatic RCC analysis \[[@R28]\], this polymorphism was shown to predict for sorafenib (an anti-VEGFR) efficacy. Promising results have been also described in metastatic colorectal cancer where this VEGFR2 polymorphism was significantly associated with increased PFS and OS in multivariate analysis in metastatic patients treated with first-line oxaliplatin-based chemotherapy regardless the KRAS mutational status \[[@R29]\]. Likewise a study in patients with localized colorectal cancer suggested a protective role for rs2071559, especially in patients that had received chemotherapy \[[@R27]\]. Data from other tumor types also pointed in a similar direction. An analysis in hepatocellular carcinoma patients treated with sorafenib showed that the presence of rs2071559 was a predictor of better outcomes \[[@R30]\]. SNPs in VEGFR3 were also associated with treatment outcomes. Thus, the absence of the SNPs rs307826 and rs6877011 were predictors of better outcome. This is consistent with other reports in RCC patients treated with the anti-VEGFR sunitinib where the presence of the genetic variant rs307826 or rs6877011 was associated with a shorter DFS \[[@R19]\] and OS \[[@R31]\].

Our study also found that SNPs in the PDGFRA gene such as rs2228230 significantly associated with worse prognosis. No previous reports exist about this SNP in RCC. Its presence has been reported in rare cancers such as extra-intestinal stromal tumors and cervical adeno-squamous carcinoma, nevertheless its prognostic or predictive role remains largely unexplored \[[@R32], [@R33]\]. In our series we could not confirm a variation in response to different PDGFR-inhibitors such as sunitinib or sorafenib based on the presence of this SNP. The limited sample size when stratifying by treatment arms could explain these results.

Three SNPs were found relevant at predicting survival in advanced RCC patients. One of them in the Interleukin 8 (IL8) gene (rs2227543) is a 3 prime UTR variant, and therefore variations in these regions could significantly impact in the metabolism of the protein. IL-8 is a pro-inflammatory chemokine that execute an angiogenic function, thus, variations on this gene could influence tumor cell growth and angiogenesis. Only one report has associated this SNP with cancer, suggesting a potential role of genetic variations in IL genes as predictors of shorter DFS and OS in colorectal tumors. \[[@R34]\]. Likewise in our series, the presence of this genetic variant was associated with shorter OS.

The other two SNPs relevant in the advanced cohort (rs9800958 and rs2302273) are located in PRKAR1B, an oncogene related with cell growth and PDGFRB respectively. Both demonstrated a protective effect in our series with longer OS for the patients that harbour these variants. Rs9800958 is an intron variant of PRKAR1B and rs2302273 is located in the 5 prime UTR variant of PDGFRB and therefore could affect the gene product by altering the binding of the transcription factor \[[@R35]\]. However, no data about the precise role of these SNPs in cancer has been communicated yet.

When looking at prediction of response SNPs in the VEGFA gene resulted of interest. The polymorphism rs699947 predicted worse prognosis in our analysis. This variant has been evaluated in metastatic RCC by other groups with contradictory results. In some series appears as a positive prognostic factor \[[@R28], [@R36], [@R37]\] while others deny its prognostic or predictive value \[[@R19], [@R38]\]. In the same gene, the presence of rs3025010 in our series was associated to worse prognosis. There are only two oncology reports about this SNP, one in non-small cell lung cancer \[[@R39]\] and other in hepatocellular carcinoma \[[@R40]\] but neither of them established any correlation between the SNP and the response rate.

On the other hand, the presence of rs594942 in VEGFB has been associated with better response in our series. We have found only one citation of this polymorphism in metastatic colorectal cancer but without significance in the study \[[@R41]\].

All these results show the variability on the interpretation of polymorphisms depending on the type of cancer or the populations where they are evaluated. Nevertheless, the present exploratory study identified a set of SNPs that could improve prognostic and predictive estimation in RCC patients. Yet, the study might have a number of limitations that need to be taken into account. First the treatment varied across patients, although the majority (86%) received tyrosine kinase inhibitors targeting VEGFR/PDGR. This fact could compromise the real predictive value of these genetic variants. Another limitation of the study is the multiple testing. In a relatively small cohort of patients, multiple SNPs (variables) are evaluated. Therefore, these results need to be cautiously interpreted and require further validation in larger series. Yet, the data here presented are hypothesis generating and could eventually help in optimizing patient selection in cancer therapeutics and improve prognostic estimation through genetic characterization.

MATERIALS AND METHODS {#s4}
=====================

Selection and characteristics of patients {#s4_1}
-----------------------------------------

Patients with localized and advanced RCC treated in the University Hospital "Virgen del Rocío" in the period 2000--2013 were included in the study. Paraffin embedded tumor samples were collected and patients were divided in two cohorts: those with localized disease and those with advanced RCC. The study protocol was approved by the Ethic Committee of Biomedical Investigation of Andalucía and conducted according to the principles of the Declaration of Helsinki.

The following inclusion criteria were considered: histologically confirmed diagnosis of primary RCC, complete clinical information and adequate tissue available (60%--75%). As clinical data the following were included: sex, age, date of diagnosis, TNM stage, histological type, tumor differentiation (Furhman grade), surgical treatment (partial or complete nephrectomy), systemic treatment (tyrosine kinase inhibitor (TKI) or mammalian target of rapamycin (mTOR) inhibitor, grade 3 or 4 toxicities, date of last visit or death and cause of death. All patients were treated following clinical guidelines and scientific evidence. Objective response was classified according to RECIST 1.1 as complete response (CR), partial response (PR), stable disease (SD), or progression of disease (PD).

Selection of SNPs involved in angiogenesis and/or metabolism of antiangiogenic drugs {#s4_2}
------------------------------------------------------------------------------------

Sixty-four SNPs in 18 genes involved in angiogenesis and the mechanism of action of the drugs utilized in RCC therapeutics were selected (VEGFA, VEGFB, VEGFC, VEGFR2, VEGFR3, PRKAR1B, PDGFB, PDGFRA, PDGFRB, ABCB1, ABCG2, NR1/2, NR1/3, CYP3A4, CYP3A5, VHL, IL-8, IL-6) (Table [4](#T4){ref-type="table"}). The selection of the SNPs to be analyzed was not systematic. Given the particular biology of RCC and the drugs utilized for treatment of this cancer we first selected genes involved in angiogenesis and also those related to the mechanism of action of tyrosine kinase inhibitors targeting VEGFR/PDGFR. Additionally we took into consideration previous studies, allele frequency in European and Iberian population (reference 100 Genomes Project), Hardy-Weinberg Equilibrium (Genotype frequencies are determined by allele frequencies at that locus) and linkage disequilibrium between SNPs determined by Haploview v4.2 software. This can be perceived as a limitation of the study \[[@R42]\]. Indeterminate results were coded as missing values for statistical analysis.

###### SNPs in genes related with angiogenesis or metabolism of antiangiogenics in RCC

  GENE          SNP                                                                                      
  ------------- ------------ ----------- ------------ ------------ ------------ ----------- ------------ ------------
  **VEGFA**     rs699947     rs833061    rs3025010    rs3025033    rs2010963    rs1570360   rs3025039    
  **VEGFB**     rs4930152    rs594942                                                                    
  **VEGFC**     rs2016110    rs1485766   rs11947611   rs2877967    rs4604006                             
  **VEGFR2**    rs2305948    rs1870377   rs12505758   rs10013228   rs11941492   rs2071559   rs1531290    rs6828477
  **VEGFR3**    rs307826     rs307821    rs6877011                                                       
  **PRKAR1B**   rs9800958    rs9768991                                                                   
  **PDGFB**     rs9611117    rs879180                                                                    
  **PDGFRA**    rs35597368   rs2114039   rs6554162    rs1800812    rs4358459    rs2228230   rs17739921   
  **PDGFRB**    rs246395     rs246394    rs3816018    rs17708574   rs2302273    rs3828610   rs2304060    rs17656204
  rs11748255    rs11740355   rs3776081   rs4324662                                                       
  **ABCB1**     rs1045642    rs1128503   rs2032582                                                       
  **ABCG2**     rs2231142                                                                                
  **NR1/2**     rs3814055    rs2276707                                                                   
  **NR1/3**     rs2307424    rs4073054                                                                   
  **CYP3A4**    rs2740574                                                                                
  **CYP3A5**    rs776746                                                                                 
  **VHL**       rs779805     rs1642742                                                                   
  **IL-8**      rs2227543    rs4073                                                                      
  **IL-6**      rs1800795                                                                                

DNA isolation and quantification {#s4_3}
--------------------------------

Paraffin embedded samples from patients with RCC were obtained from surgical specimens from nephrectomy. For each sample of 10 µm, paraffin was removed and DNA was isolated with DNA kit QiAGEN protocol. DNA concentration was determined by Nanodrop (Thermo Scientific, DE, USA).

Amplification of the samples and TaqMan SNP assays {#s4_4}
--------------------------------------------------

DNA was amplified, mixing 20 ng/µl of each DNA with the PreAmp Master Mix and PreAmp Pool (Life Technologies, Madrid, Spain) in 96-plate wells. This plate was sealed with MicroAmp clear adhesive film, centrifuged 30 s and put into GeneAmp PCR System 9700 that is specifically designed for the amplification of nucleic acids using the Polymerase Chain Reaction (PCR) process. The PCR conditions were: hold 95°C, 10 min; denature 95°C, 15 sec, 16 cycles and anneal/extend 60°C, 4 min, 16 cycles. Afterwards, each sample was diluted (1/20) with buffer TE (Tris-EDTA). The plate could be used immediately or kept at --20°C until next day. Samples were transferred duplicated into microArrays by a robotic axis. The result were obtained and interpreted by the TaqMan Genotyper Software (Life Technologies).

Statistical analysis {#s4_5}
--------------------

The primary objective in the localized tumors cohort was to correlate the presence of SNPs with a worse DFS and OS. DFS was defined as the time between the diagnosis and the date of a radiological progression or death and OS as the time between the diagnosis and the date of death or last date of follow-up.

In the metastatic patients cohort overall RR, PFS and OS were analyzed and correlated with the presence SNPs. We considered overall RR as the percentage of CR and PR. The PFS was defined as the interval between the first day on systemic treatment and the date of radiological PD or death. Overall survival was defined as the time between the first day on treatment and the date of death or last date of follow-up.

Descriptive statistics were used to define the most relevant clinical features. The chi-squared test or Fisher's exact test were used in order to know the most relevant clinical variables to be included in the multivariate analysis. For this purpose, the DFS, PFS and OS parameters and RR variables with *p* \< 0.25 or those considered clinically relevant based on the previous literature on RCC were selected. These characteristics were: for patients with localized disease: type of nephrectomy (partial/complete), Furhman Grade (3--4), TNM stage and for patients with metastatic disease: Furhman Grade (3--4), TNM stage prognosis group (favorable vs intermediate/poor), metastasis lung and/or bones, Karnofsky, hemoglobin, time between nephrectomy and systemic treatment. ECOG was not included because the low number of patients in localized disease. All SNPs were tested in a univariant analysis for association with DFS, PFS and OS using Kaplan-Meier statistics and in a multivariate analysis using Cox proportional hazards to know the association between the presence of each SNPs and survival adjusting for potential confounding factors. Patients who had not progressed at database closure were censored at last follow-up. Also a chi-squared and a logistic regression were used to compare the presence of the SNPs and worse RR and the association of grade 3--4 toxicity with the presence of certain SNPs. *P \<* 0.05 was considered significant. All analyses were performed using the Statistical Package for the Social Sciences software (SPSS 20.0 for Windows; SPSS Inc, Chicago, IL).
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